Cardiovascular safety of empagliflozin in patients with type 2 diabetes: a meta‐analysis of data from randomized placebo‐controlled trials

AIM: To assess the effect of empagliflozin on cardiovascular (CV) risk in patients with type 2 diabetes (T2DM) through a meta‐analysis of data from eight placebo‐controlled trials. METHODS: Data were analysed from eight randomized placebo‐controlled trials undertaken to investigate the efficacy and...

Descripción completa

Detalles Bibliográficos
Autores principales: Salsali, A., Kim, G., Woerle, H. J., Broedl, U. C., Hantel, S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2016
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096016/
https://www.ncbi.nlm.nih.gov/pubmed/27376831
http://dx.doi.org/10.1111/dom.12734

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096016/
https://www.ncbi.nlm.nih.gov/pubmed/27376831
http://dx.doi.org/10.1111/dom.12734

Ejemplares similares